JP2000517341A - マトリックスメタロプロテイナーゼ阻害剤およびそれらの治療的使用 - Google Patents

マトリックスメタロプロテイナーゼ阻害剤およびそれらの治療的使用

Info

Publication number
JP2000517341A
JP2000517341A JP10512709A JP51270998A JP2000517341A JP 2000517341 A JP2000517341 A JP 2000517341A JP 10512709 A JP10512709 A JP 10512709A JP 51270998 A JP51270998 A JP 51270998A JP 2000517341 A JP2000517341 A JP 2000517341A
Authority
JP
Japan
Prior art keywords
alkyl
patient
sulfonylamino
dibenzofuran
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10512709A
Other languages
English (en)
Japanese (ja)
Inventor
オブライエン，パトリック・マイクル
ピカード，ジョウゼフ・アーマンド
スリスコーヴィク，ドラーゴウ・ロバート
ホワイト，アンドルー・デイヴィッド
Original Assignee
ワーナー―ランバート・コンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワーナー―ランバート・コンパニー filed Critical ワーナー―ランバート・コンパニー
Publication of JP2000517341A publication Critical patent/JP2000517341A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP10512709A 1996-09-04 1997-08-22 マトリックスメタロプロテイナーゼ阻害剤およびそれらの治療的使用 Pending JP2000517341A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2506296P 1996-09-04 1996-09-04
US5571397P 1997-08-07 1997-08-07
US60/025,062 1997-08-07
US60/055,713 1997-08-07
PCT/US1997/014859 WO1998009934A1 (fr) 1996-09-04 1997-08-22 Inhibiteurs de metalloproteinases matricielles et leurs utilisations pharmaceutiques

Publications (1)

Publication Number Publication Date
JP2000517341A true JP2000517341A (ja) 2000-12-26

Family

ID=26699216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10512709A Pending JP2000517341A (ja) 1996-09-04 1997-08-22 マトリックスメタロプロテイナーゼ阻害剤およびそれらの治療的使用

Country Status (8)

Country Link
EP (1) EP0931045A1 (fr)
JP (1) JP2000517341A (fr)
KR (1) KR20000068414A (fr)
AU (1) AU735013B2 (fr)
BR (1) BR9711988A (fr)
CA (1) CA2256716A1 (fr)
NZ (1) NZ333063A (fr)
WO (1) WO1998009934A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000068415A (ko) 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법
NZ334897A (en) * 1996-12-09 2001-02-23 Warner Lambert Co Medicaments for treating and preventing heart failure and ventricular dilatation
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
PL346011A1 (en) * 1998-07-21 2002-01-14 Warner Lambert Co Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
AU758619B2 (en) 1998-07-30 2003-03-27 Warner-Lambert Company Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
WO2000006560A1 (fr) * 1998-07-30 2000-02-10 Warner-Lambert Company Composes heteroaromatiques tricycliques et leurs derives utilises comme inhibiteurs des metalloproteinases matricielles
AU5647099A (en) * 1998-09-11 2000-04-03 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure
DE60120881T2 (de) * 2000-04-07 2007-01-18 Samsung Electronics Co., Ltd., Suwon Sulfonamide als matrix-metalloproteinase inhibitoren
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
ATE380185T1 (de) 2002-10-23 2007-12-15 Glenmark Pharmaceuticals Ltd Tricyclische verbindungen zur behandlung von entzündlichen- und allergischen erkrankungen: verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
EP1620429B1 (fr) 2003-04-11 2009-04-01 Glenmark Pharmaceuticals S.A. Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant
WO2004111044A1 (fr) * 2003-06-17 2004-12-23 Glenmark Pharmaceuticals Ltd. Composes tricycliques efficaces dans le traitement des affections inflammatoires et allergiques : leur procede de preparation
BRPI0516341A (pt) 2004-10-13 2008-09-02 Glenmark Pharmaceuticals Sa método para preparação de intermediários de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida, método para a preparação de compostos intermediários de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida, n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzeno [b,d] furano-1-carboxamida, método para a sìntese de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida e seu sal sódico de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida
SI1831227T1 (sl) 2004-12-17 2013-09-30 Glenmark Pharmaceuticals S.A. Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
WO2008057254A2 (fr) * 2006-10-27 2008-05-15 Wyeth Composés tricycliques servant d'inhibiteurs des métalloprotéases matricielles
AR066412A1 (es) * 2007-05-04 2009-08-19 Wyeth Corp Derivados de dibenzofurano y dibenzotiofeno, composiciones farmaceuticas que los contienen y usos en patologias tales como trastornos oseos, crecimiento de tumores, diabetes y obesidad.
CN105906665B (zh) * 2016-05-16 2017-11-28 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物前药或其可药用盐及其制备方法和应用
WO2021147882A1 (fr) * 2020-01-21 2021-07-29 深圳信立泰药业股份有限公司 Inhibiteur de la cathepsine k dérivé du dibenzofurane, son procédé de préparation et son utilisation médicale

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2065966C3 (de) * 1969-09-06 1978-11-16 Ajinomoto Co., Inc., Tokio N-Fluorenyl-sulfonyl-aminocarbonsäuren sowie diese enthaltende Mittel
NL7013043A (fr) * 1969-09-06 1971-03-09
US3845097A (en) * 1969-09-06 1974-10-29 Ajinomoto Kk N-substituted amino acids and novel ester
US4097472A (en) * 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
DE3577700D1 (de) * 1984-11-30 1990-06-21 Shosuke Okamoto Lysinderivat und proteinase-inhibitor.
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
PT828726E (pt) * 1995-06-02 2002-03-28 Warner Lambert Co Inibidores triciclicos de metaloproteinases de matriz
PL326700A1 (en) * 1995-11-17 1998-10-26 Warner Lambert Co Sulphonamide-based inhibitors of intercellular substance metaloproteinases
SK282995B6 (sk) * 1996-01-23 2003-01-09 Shionogi And Co., Ltd. Zlúčenina na inhibíciu metaloproteázy a prostriedok s jej obsahom

Also Published As

Publication number Publication date
AU735013B2 (en) 2001-06-28
KR20000068414A (ko) 2000-11-25
BR9711988A (pt) 1999-08-24
AU4159597A (en) 1998-03-26
CA2256716A1 (fr) 1998-03-12
NZ333063A (en) 2000-12-22
WO1998009934A1 (fr) 1998-03-12
EP0931045A1 (fr) 1999-07-28

Similar Documents

Publication Publication Date Title
JP2000517341A (ja) マトリックスメタロプロテイナーゼ阻害剤およびそれらの治療的使用
JP2002514180A (ja) マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法
JP2000514779A (ja) マトリックスメタロプロティナーゼのスルホンアミド阻害剤
US6117869A (en) Compounds for and methods of inhibiting matrix metalloproteinases
EP0586537A1 (fr) Derives substitues n-carboxyalkylpeptidyle en tant qu'agents antidegeneratifs
JP2013240326A (ja) 癌および皮膚病変の処置のためのグリコシルホスファチジルイノシトール（ｇｐｉ）アンカーに連結されたメタロプロテイナーゼの組織インヒビター
AU758619B2 (en) Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
ES2216938T3 (es) Compuestos de acido hidroxamico utiles como inhibidores de metaloproteinasas de matriz.
CZ195298A3 (cs) Aromatické keto-kyseliny a jejich deriváty jako inhibitory matricových metaloproteináz
EP0828726B1 (fr) Inhibiteurs tricycliques de metalloproteinases matricielles
US6624177B1 (en) Matrix metalloproteinase inhibitors and their therapeutic uses
MXPA98009871A (en) Matrix metalloproteinase inhibitors and their therapeutic uses
US5932551A (en) Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative active agents
JP2006500422A (ja) 酵素活性を阻害するためのキレート化剤の親油性ジエステル
MXPA98009929A (en) Compounds for and a method of inhibiting matrix metalloproteinases